Celltrion, an Incheon, South Korea-based biopharmaceutical company of biosimilars and innovator drugs, plans to launch a contract development and manufacturing business, Bio CDMO.  

Celltrion says that Bio CDMO will handle outsourcing of biologic cell-line development and development of production processes as well as manufacture non-clinical material, clinical material, and commercialized material.

Celltrion says the new CDMO business will focus on collaborating with research institutes and biotechnology firms for commercializing new drug candidates. Celltrion plans to support partnered firms by offering Celltrion’s biologics development skills, and may, through consultation and discussion, provide development costs or licenses for the molecule(s).

Celltrion is initially focusing on specific therapeutic areas that have the greatest synergy with Celltrion’s product portfolio , such as autoimmune diseases (rheumatoid arthritis, inflammatory bowel diseases, etc.), breast cancer, lymphoma, and cardiovascular diseases.

Source: Celltrion